Company Overview of Xiehe Group
Xiehe Group operates as a bio pharmaceutical company in China. It develops super antigen based anti-cancer bio-preparation for the treatment of tumors; and activates cytotoxicity t lymphocyte, natural killer cell, and superantigen dependent cell-mediated cytotoxicity to boost immunity. The company offers staphylococcal enterotoxin C injection, an injection that protects patients from relieving leucopenia caused by radio-chemotherapy and support body’s immune function. Xiehe Group’s product is also used in combination with radio-chemotherapy to treat malignant tumor; and used in fracture to treat delayed healing or not healing. The company was founded in 1988 and is based in Shenyang, China.
No. 30 Gaoke Road Hunnan High and New Tech Industrial DevelopmentZone
Founded in 1988
86 24 2378 4596
86 24 2378 7042
Key Executives for Xiehe Group
Similar Private Companies By Industry
|3D BioOptima Co. Ltd.||Asia|
|Adagene (Suzhou) Limited||Asia|
|AGCU ScienTech Incorporation||Asia|
|Anhui Life Co.,Ltd.||Asia|
|Anhui Puyuan Biotechnology Co., Ltd.||Asia|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Xiehe Group, please visit www.xiehegroup.com.cn. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.